Abudoureyimu Alimujiang, Aihaiti Alimu, Abudoujilili Nuliman, Tuergong Mayila, Adili Guzainuer, Maimaiti Maihebubaimu, Mohetaer Dilinuer, Maiamaitishawuti Yimamumaimaiti
Department of Cardiology, The First People's Hospital of Kashi Prefecture, Kashi, China.
J Diabetes Res. 2024 Nov 23;2024:9378405. doi: 10.1155/2024/9378405. eCollection 2024.
This study investigates the impact of a high-sugar environment on H9C2 cardiomyocytes and explores the protective effects of carvedilol in the context of diabetic cardiomyopathy (Dia-CM). Transcriptomic analysis identified 21,655 differentially expressed genes associated with Dia-CM, demonstrating significant separation among samples. H9C2 cardiomyocytes were cultured in a high-sugar environment to simulate Dia-CM conditions. Cell viability, cytokine levels, and protein expression were assessed using CCK-8 assays, ELISA, and Western blot techniques. Intervention experiments with NLRP3, caspase-1, and ROS inhibitors were conducted to evaluate their protective effects. The therapeutic potential of carvedilol was assessed by examining its impact on cell viability, cytokine levels, and key biomarkers. An in-depth analysis of carvedilol's regulatory effects on ROS and key proteins in H9C2 cells was also conducted. In vitro, a high-sugar environment significantly reduced H9C2 cell survival, increased ROS levels, activated inflammatory responses, and upregulated NLRP3, caspase-1, and GSDMD-N proteins. Inhibitors of NLRP3, caspase-1, and ROS ameliorated these effects. Carvedilol treatment improved cell activity, reduced inflammatory cytokine levels, suppressed ROS production, and downregulated NLRP3, pro-caspase-1, GSDMD-N, and p-NF-B proteins. Moderate-dose carvedilol exhibited optimal intervention effects. A high-sugar environment induces cardiomyocyte damage through ROS production and NLRP3 inflammasome activation. Inhibitors of NLRP3, caspase-1, and ROS provide effective protection. Carvedilol significantly mitigates the detrimental effects of a high-sugar environment on H9C2 cardiomyocytes, potentially through inhibiting the NLRP3-ASC inflammasome and caspase-1/GSDMD-dependent signaling pathway-mediated pyroptosis. These findings offer insights into Dia-CM mechanisms and highlight carvedilol as a promising therapeutic intervention.
本研究调查高糖环境对H9C2心肌细胞的影响,并探讨卡维地洛在糖尿病性心肌病(Dia-CM)背景下的保护作用。转录组分析鉴定出21,655个与Dia-CM相关的差异表达基因,表明样本之间存在显著分离。将H9C2心肌细胞在高糖环境中培养以模拟Dia-CM条件。使用CCK-8测定、ELISA和蛋白质印迹技术评估细胞活力、细胞因子水平和蛋白质表达。进行了NLRP3、半胱天冬酶-1和活性氧(ROS)抑制剂的干预实验以评估其保护作用。通过检查卡维地洛对细胞活力、细胞因子水平和关键生物标志物的影响来评估其治疗潜力。还对卡维地洛对H9C2细胞中ROS和关键蛋白的调节作用进行了深入分析。在体外,高糖环境显著降低H9C2细胞存活率,增加ROS水平,激活炎症反应,并上调NLRP3、半胱天冬酶-1和Gasdermin D-N(GSDMD-N)蛋白。NLRP3、半胱天冬酶-1和ROS的抑制剂改善了这些作用。卡维地洛治疗提高了细胞活性,降低了炎症细胞因子水平,抑制了ROS产生,并下调了NLRP3、前半胱天冬酶-1、GSDMD-N和磷酸化核因子-κB(p-NF-κB)蛋白。中等剂量的卡维地洛表现出最佳干预效果。高糖环境通过ROS产生和NLRP3炎性小体激活诱导心肌细胞损伤。NLRP3、半胱天冬酶-1和ROS的抑制剂提供有效的保护作用。卡维地洛显著减轻高糖环境对H9C2心肌细胞的有害影响,可能是通过抑制NLRP3-凋亡相关斑点样蛋白(ASC)炎性小体和半胱天冬酶-1/GSDMD依赖性信号通路介导的细胞焦亡。这些发现为Dia-CM机制提供了见解,并突出了卡维地洛作为一种有前景的治疗干预措施。